Shareholders that lost money on Applied Therapeutics, Inc.(APLT) should contact Levi & Korsinsky about pending Class Action - APLT
NEW YORK, NY / ACCESSWIRE / December 17, 2024 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Therapeutics, Inc. - APLT
NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ:APLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Applied Therapeutics, Inc. (APLT) And Encourages Investors to Connect
NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT). Investors who purchased Applied Therapeutics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLT.
An Investigation Has Commenced on Behalf of Applied Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your APLT Losses
NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Therapeutics, Inc. - APLT
NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ:APLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Shareholders that lost money on Applied Therapeutics, Inc.(APLT) should contact Levi & Korsinsky about Securities Fraud Investigation - APLT
NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.
Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Stockholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT). Investors who purchased Applied Therapeutics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLT.
Levi & Korsinsky Reminds Applied Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - APLT
NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Therapeutics, Inc. - APLT
NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Therapeutics, Inc. - APLT
NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Levi & Korsinsky Announces an Investigation on Behalf of Applied Therapeutics, Inc. (APLT) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Applied Therapeutics, Inc. (APLT) And Encourages Stockholders to Reach Out
NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT). Investors who purchased Applied Therapeutics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLT.
